Mounjaro in Japan: ATEOS, strengths, label details, and request checklist.

This page helps international visitors identify Japan-listed Mounjaro information before contacting support. It focuses on Japanese product wording, active ingredient, ATEOS device format, strength confirmation, storage, and consultation preparation.

Contact support with product details

What “Mounjaro in Japan” means

Here, “Japan” refers to the Japanese product information environment: Japanese brand wording, package format, strength naming, patient-information sheets, cold-chain expectations, and the support checks needed before any cross-border follow-up.

It does not mean this page compares medical suitability across countries or replaces guidance from a qualified healthcare professional.

Japanese name and product format

マンジャロ

The Japanese brand name for Mounjaro.

皮下注

Subcutaneous injection. This tells support the product is an injectable medicine, not a tablet.

アテオス

ATEOS indicates the prefilled injection-device format used in Japanese Mounjaro listings.

Strengths to confirm

When asking about Mounjaro, always provide the exact strength. “Mounjaro” alone is not enough for support to identify the requested product.

Strength	How to write it in a request	What support checks
2.5 mg	Mounjaro Subcutaneous Injection 2.5 mg ATEOS	Starter-stage context, quantity, cold-chain handling, and destination rules.
5 mg	Mounjaro Subcutaneous Injection 5 mg ATEOS	Continuation context, quantity, cold-chain feasibility.
7.5 mg	Mounjaro Subcutaneous Injection 7.5 mg ATEOS	Whether dose escalation is medically supervised.
10 mg	Mounjaro Subcutaneous Injection 10 mg ATEOS	Use context, availability, destination restrictions.
12.5 mg	Mounjaro Subcutaneous Injection 12.5 mg ATEOS	Higher-dose context and supporting information.
15 mg	Mounjaro Subcutaneous Injection 15 mg ATEOS	Maximum listed strength context; medical review is especially important.

Medical information summary

Japanese patient-information materials identify tirzepatide as the active ingredient. Mounjaro is described as a glucose-dependent insulinotropic polypeptide (GIP) / glucagon-like peptide-1 (GLP-1) receptor agonist and is usually used for treatment of type 2 diabetes mellitus under medical direction.

Japanese materials describe once-weekly subcutaneous injection and stepwise dose adjustment under physician guidance. Dose selection and adjustment should be handled by a qualified medical professional, not by this website or support chat.

Storage and handling checks

Mounjaro is an injectable medicine, so storage and transit conditions matter. Support may need to check cold-chain packaging, destination country, transit time, and whether the requested quantity is realistic for the route.

Do not assume that an injectable medicine can be handled the same way as tablets. Temperature exposure, shipment route, customs rules, quantity, and product-category restrictions can affect whether support can proceed.

Safety points to mention before requesting

Tell your physician and support staff if any of the following are relevant:

Type 1 diabetes, diabetic ketoacidosis, diabetic coma or precoma.
Severe infection, surgery, or other urgent medical situation.
History of pancreatitis.
Severe gastrointestinal disorders such as gastroparesis.
Pregnancy, breastfeeding, or planning pregnancy.
Use of insulin, sulfonylureas, or other glucose-lowering medicines.
Low food intake, heavy alcohol use, or strenuous physical exercise.
History of diabetic retinopathy requiring treatment.

Common side effects discussed in product materials

Commonly discussed reactions include nausea, vomiting, diarrhea, abdominal discomfort, constipation, and low blood sugar risk, especially when combined with other glucose-lowering medicines. If symptoms are severe or urgent, contact a qualified healthcare provider or local emergency service.

Request checklist

Exact product name: Mounjaro Subcutaneous Injection strength ATEOS.
Japanese name or package screenshot if available.
Strength and quantity.
Destination country or region.
Whether you are starting, continuing, or switching from another GLP-1 medicine.
Whether you are starting, continuing, or switching from another GLP-1 medicine.
Any relevant medical history or medicines that could affect safety.
Whether cold-chain handling is required for your route.

Mounjaro Japan FAQ

Is Mounjaro Japan the same as tirzepatide?

Mounjaro is the brand name. Tirzepatide is the active ingredient. A request should include both the brand and the exact strength.

What does ATEOS mean?

ATEOS refers to the Japanese prefilled injection-device format. It helps distinguish the product from tablets, vials, or other injection formats.

Can support choose my Mounjaro dose?

No. Dose selection and changes must be handled by a qualified healthcare professional. Support can help identify product details.

Why is cold-chain handling important?

Mounjaro is an injectable product. Temperature exposure, route, and destination rules can affect whether support can proceed.

What should I send first?

Send strength, quantity, destination country, cold-chain concern, and whether you are starting, continuing, or switching from another GLP-1 medicine.

Is availability guaranteed?

No. Availability, shipment feasibility, and destination-country import rules must be checked before any next step.

Related GLP-1 pages

GLP-1 comparison guide

Compare Mounjaro, Ozempic, Wegovy, and Rybelsus in Japan.

Ozempic Japan

Semaglutide injection page for visitors comparing Mounjaro and Ozempic.

Contact checklist

Use the support template to send strength, quantity, destination country, and cold-chain context.

Ask support with complete product details.

Use the contact page to send the strength, quantity, destination country, cold-chain context, and whether this is starting, continuing, or switching.

Contact support

MedGuide Japan provides product-information support only. We do not diagnose, choose doses, replace medical advice, or guarantee availability.